Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233) | Zendy

John Anderson | Zendy; Ghandi Al-Ali | Zendy; Manfred Wirth | Zendy; Joan Benejam Gual | Zendy; Francisco Gómez Veiga | Zendy; Enrico Colli | Zendy; Egbert van der Meulen | Zendy; BoEric Persson | Zendy

Open Access

Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)

Author(s) -

John Anderson,

Ghandi Al-Ali,

Manfred Wirth,

Joan Benejam Gual,

Francisco Gómez Veiga,

Enrico Colli,

Egbert van der Meulen,

BoEric Persson

Publication year - 2012

Publication title -

urologia internationalis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.771

H-Index - 53

eISSN - 1423-0399

pISSN - 0042-1138

DOI - 10.1159/000345423

Subject(s) - medicine , prostate cancer , urology , tolerability , goserelin , clinical endpoint , lower urinary tract symptoms , antiandrogen , adverse effect , bicalutamide , gynecology , prostate , cancer , clinical trial , androgen receptor

No studies to date have assessed the efficacy/tolerability of degarelix in the relief of lower urinary tract symptoms (LUTS) secondary to prostate cancer (PrCa).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research